Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
d9 Designs has developed Deura9™ (“d9-Caffeine”), a deuterated form of caffeine with enhanced stability, longer duration of action, smoother energy delivery, reduced tolerance buildup, and improved skin benefits. Clinical studies have shown that d9-caffeine achieves higher sustained levels than conventional caffeine with fewer side effects. The product is Generally Recognized As Safe (GRAS) for use in foods in the US. It is being commercialized both directly and via partnerships/licensing for beverage and skincare markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on d9 Designs.